{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-03-18",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Princeton",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "81485",
      "recalling_firm": "Sandoz, Inc",
      "address_1": "506 Carnegie Ctr Ste 400",
      "address_2": "N/A",
      "postal_code": "08540-6243",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "OH, PR",
      "recall_number": "D-0359-2019",
      "product_description": "Sandoz Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/25 mg,  1000-count bottles, Rx Only, Finished Drug Product Manufactured by:  Lek Pharmaceuticals d.d. SI-1526 Ljubljana,Sovenia for Sandoz Inc., Princeton, NJ   08540, NDC 0781-5207-10.",
      "product_quantity": "170 HDPE bottles",
      "reason_for_recall": "CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above  the interim acceptable daily intake level of 0.083 parts per million.",
      "recall_initiation_date": "20181101",
      "center_classification_date": "20190114",
      "report_date": "20181205",
      "code_info": "Lot #: JB8912; Exp. 06/2020"
    }
  ]
}